Biotechnology

SOHM, Inc. has Received ABBIE Technology Kits' Pre-Launch Pre-Orders

September 25, 2024 9:45 AM

SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs, has announced today that the company has received ABBIE Technology kits pre-launch orders. Dr. David Aguilar, COO, shared that the company has received pre-launch and pre-orders for our ABBIE technology kits. This is significant miles stone for the company and we are very happy to transition from Research and Development to commercialization of...

Read more

Moolec Science to Host Fourth Quarter Fiscal Year 2024 Business Update Conference Call

September 25, 2024 6:00 AM

LUXEMBOURG / ACCESSWIRE / September 25, 2024 / Moolec Science SA (NASDAQ:MLEC)("The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, announced today that it will release its Business Update for the Fourth Quarter and Full Fiscal Year 2024 on Wednesday, October 2, 2024, before the market opens. Moolec Sciences Logo Moolec's Chief Executive Officer Gastón Paladini,...

Read more

Adolore BioTherapeutics to Present at BioSparkVA Pitch Event

September 24, 2024 8:20 AM

Adolore BioTherapeutics, Inc., ("Adolore" or the "Company"), a biotechnology company developing transformational opioid-free intracellularly-delivered treatments for chronic pain, today announced that Roy C. Levitt, MD, the Company's founder and Executive Chairman, Chief Medical Officer, Clinical Professor, University of Miami, and Principal Investigator of a NIH, NINDS, HEAL UH3 Award will present at BioSparkVA's BioSpark Pitch Event, hosted by...

Read more

Ensysce Biosciences Presenting at Upcoming Meetings

September 24, 2024 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / September 24, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced its participation in two upcoming meetings in October 2024. October 5, 2024: New data will be presented in a poster session in collaboration with Sygnature...

Read more

Cloud Storage Security Names Kevin Hunt as Chief Technology Officer

September 24, 2024 8:00 AM

Cloud Storage Security (CSS), a leader in advanced threat detection and data loss prevention for cloud-native applications, today announced that Kevin Hunt has joined the company as chief technology officer. In this capacity, he is responsible for leading CSS's technical vision across product development, engineering, and customer experience. Hunt brings to CSS a wealth of experience in leading product teams and driving technological...

Read more

Enalare Receives FDA Clearance to Initiate the First Phase 1 Clinical Study of ENA-001 to Be Conducted in the United States

September 24, 2024 8:00 AM

PRINCETON, NJ / ACCESSWIRE / September 24, 2024 / Enalare Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing novel compounds for the treatment of life-threatening critical care conditions and community health emergencies, today announced that is has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a phase I clinical study of ENA-001 that supports the proposed indication for...

Read more

Biovica Announces Subscription Commitments in Ongoing TO3B Program

September 24, 2024 7:45 AM

UPPSALA, SWEDEN / ACCESSWIRE / September 24, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Monday, September 30, 2024, is the last day for subscription in Biovica's ongoing warrant program, TO3B. Note that some banks and asset managers may have an earlier deadline date for subscription than 30 September 2024. Shareholders should check this with their bank or trustee in order not to miss the chance to subscribe for shares or...

Read more

Longwood Healthcare Leaders' Flagship Meeting Boston CEO to Convene Life Science Thought Leaders Across Government, Pharma, Biotech, Academia, and Research

September 24, 2024 7:00 AM

BOSTON, MA / ACCESSWIRE / September 24, 2024 / Longwood Healthcare Leaders will convene top biopharmaceutical executives for two days of discussion and networking at Boston CEO, a leading industry meeting co-hosted by Christoph Westphal, John Maraganore, Ted Love, Marcus Schindler, Susan Hockfield, and Mathai Mammen, held at the Mandarin Oriental Hotel, Boston, October 28-29, 2024. Longwood Healthcare Leaders Logo Longwood Healthcare Leaders...

Read more

Cenna Biosciences Receives NIH NIA Phase II SBIR Award for the Early Clinical Development of Nubytide TM, a First-in-Class, Disease-Modifying Peptide Drug for the Prevention and Treatment of Alzheimer’s Disease

September 23, 2024 6:00 PM

LA JOLLA, CA / ACCESSWIRE / September 23, 2024 / Cenna Biosciences Inc., a privately-held biopharmaceutical company based in La Jolla, California, and focused on developing novel treatments for Alzheimer's disease (AD), has been awarded a Phase II SBIR grant of $2.7M from the National Institutes of Health (NIH), National Institute on Aging (NIA), to support the early clinical development of their peptide drug NubytideTM, for the prevention and...

Read more

Biovica Signs Significant Work Order for TKa Testing Services

September 23, 2024 2:20 AM

UPPSALA, SE / ACCESSWIRE / September 23, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in blood-based cancer monitoring, has signed a work order with a value of 2.2 MSEK. This is the company's largest single work order to date for TKa testing services within its Pharma Services business. The work order is signed with a US-based biotech company focused on next-generation CDK inhibitors, which since last week...

Read more

Mölnlycke(R) and Ondine Join Forces Against HAIs

September 23, 2024 2:00 AM

Ondine Biomedical Inc. (LON:OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, and Mölnlycke Health Care (Gothenburg Sweden), a world-leading MedTech company that specializes in innovative solutions for wound care and surgical procedures, are pleased to announce a strategic partnership to bring Ondine's Steriwave® nasal decolonization technology to the United Kingdom, EU, and Middle East markets. This...

Read more

DISCOVER FH Collaboration With Family Heart Foundation, UT Southwestern, and Partners

September 20, 2024 9:00 AM

LIPID inCode tests patients to identify familial hypercholesterolemia and prevent cardiovascular disease OXFORD, ENGLAND / ACCESSWIRE / September 20, 2024 / GENinCode Plc (AIM:GENI), the genetics company focused on the prevention of cardiovascular disease and ovarian cancer, announces its collaboration with The Family Heart Foundation®, UT Southwestern, and other partner members to use the LIPID inCode® monogenic and polygenic test in US Primary...

Read more

NeuroEM Therapeutics(R) Accepted into StartUp Health's Alzheimer's Moonshot Community(TM)

September 19, 2024 8:30 AM

TAMPA, FL / ACCESSWIRE / September 19, 2024 / NeuroEM Therapeutics®, a leading clinical-stage biotechnology research company focused on commercializing its proprietary Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF) technologies against Alzheimer's disease and cognitive decline, announced today it has been accepted as a member of StartUp Health's Alzheimer's Moonshot Community™. The invitation came following a...

Read more

Ensysce Biosciences Submits Phase 3 Protocol to the FDA

September 19, 2024 7:00 AM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced it has submitted to the FDA its PF614-301 protocol of the study, "A Multicenter, Randomized, Double-Blind, Placebo-and Active-Controlled Study to Evaluate the Efficacy and Safety of PF614 for the Treatment of...

Read more

Faro Health Joins Veeva Product Partner Program

September 18, 2024 7:00 AM

Partnership enables an integration to improve the productivity of clinical development team. SAN DIEGO, CA / ACCESSWIRE / September 18, 2024 / Faro Health Inc., the leading AI-powered platform for clinical protocol design, today announced it joined the Veeva Product Partner Program. With this partnership, Faro Health will develop an integration between Faro's Study Designer and Veeva Vault EDC. Faro Health offers tools and insights for...

Read more

Vicore Publishes Prospectus Relating to the Rights Issue

September 18, 2024 6:00 AM

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OF AMERICA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. REFER TO THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE. STOCKHOLM, SE / ACCESSWIRE / September 18, 2024 / Vicore Pharma Holding...

Read more

XiltriX North America Achieves ISO 9001:2015 Recertification, Demonstrating Commitment to Continuous Quality Improvement

September 17, 2024 9:07 AM

SAN DIEGO, CA / ACCESSWIRE / September 17, 2024 / XiltriX North America is the only real-time environmental monitoring provider in the life science industry that holds ISO 9001:2015 recertification for Quality Management Systems (QMS) and a SOC 2 Type 2 attestation. This recertification highlights XiltriX's ongoing commitment to maintaining the highest standards of quality and continuous improvement in its service offerings. "We are thrilled...

Read more

New Immuno-Oncology Research Team in Partnership with Ono Pharmaceutical Starts at BioMed X Institute

September 17, 2024 6:30 AM

BioMed X, a German biomedical research institute, announced the start of a new research team at the BioMed X Institute in Heidelberg, Germany, the institute's first joint research project with the Japanese company Ono Pharmaceutical Co., Ltd. The scope of this project is to investigate the antitumor effects of neutrophils to develop novel next-generation immunotherapies. Ono Pharmaceutical and BioMed X Institute launch new collaboration in...

Read more

Announcement from Biovica International AB's Annual General Meeting

September 17, 2024 5:20 AM

UPPSALA, SE / ACCESSWIRE / September 17, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) The annual general meeting of Biovica International AB ("Biovica" or the "Company") was held today on 17 September 2024 and the following resolutions were passed by the meeting. ADOPTION OF THE INCOME STATEMENT AND BALANCE SHEET The annual general meeting resolved to adopt Biovica's income statement and balance sheet as well as the...

Read more

Biovica Signs Agreement with Clinical-Stage US Biotech Company

September 17, 2024 2:50 AM

UPPSALA, SE / ACCESSWIRE / September 17, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in blood-based cancer monitoring, has signed a Master Service Agreement (MSA) with a US-based biotech company focusing on next generation CDK inhibitors. Under the agreement, Biovica will provide TKa testing services utilizing Biovica's DiviTum® TKa assay and expertise in interpreting TKa measurement dynamics to support...

Read more